Pharmafile Logo
Pharmafocus logo
Advanced Search

Pfizer

Showing 15 posts of 894 posts found.

FDA approves Pfizer’s abuse-deterrent opioid painkiller

August 22, 2016
Sales and Marketing FDA, Pfizer, abuse deterrent, abuse-deterrent, approval, opioid, troxyca

Pfizer has announced that the US FDA has approved Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules for the …

News

Pfizer’s Xalkori price drop secures NICE recommendation

August 18, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, Pfizer, Xalkori, crizotinib, lung cancer

The National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Xalkori (crizotinib) as a treatment for lung cancer, …

News
merck_incweb

MSD joins Medivation race, says reports

August 18, 2016
Manufacturing and Production, Research and Development, Sales and Marketing MSD, Medivation, Merck, Pfizer, Sanofi, Xtandi, takeover

MSD, known as Merck in the US and Canada, is said to have declared its interest in buying US oncology …

News
pfizer_reflection

Revenue rises at Pfizer as Ibrance and Xeljanz beat sales expectations

August 2, 2016
Research and Development, Sales and Marketing 2016, Pfizer, Prevnar, Q2, Xeljanz, ibrance, results

Pfizer has published its Q2 results, which show revenues rising 11% with new drugs helping to drive the growth and …

News
pfizer_credit_flickr__ceiling

Pfizer expands gene therapy operations with acquisition of Bamboo Therapeutics

August 2, 2016
Manufacturing and Production, Research and Development Pfizer, acquisition, bamboo therapeutics, gene therapy

Pfizer has announced that it has acquired gene therapy biotech Bamboo Therapeutics for an initial $150 million, with potential milestone …

News

Ulcerative colitis treatment Xeljanz records positive top-line results in Phase III trial

July 29, 2016
Medical Communications, Research and Development Pfizer, Xeljanz, tofacitinib, ulcerative colitis

Pfizer has announced positive top-line results from oral clinical trials for tofacitinib in ulcerative colitis (Octave) sustain, the third Phase …

News

Pfizer and Spark Therapeutics granted FDA breakthrough designation for haemophilia drug

July 22, 2016
Medical Communications, Research and Development FDA, Pfizer, Spark Therapeutics, haemophilia B, spk-9001

Pfizer and Spark Therapeutics have announced that the US Food and Drug Administration (FDA) has granted a breakthrough therapy designation …

News
pfizer-building-logo1web

Pfizer announces strong Phase III results for atopic dermatitis drug

July 14, 2016
Research and Development Pfizer, anacor, atopic dermatitis, crisaborole, eczema

Pfizer (NYSE: PFE) has announced positive results from two pivotal Phase III studies for crisaborole in the treatment of mild …

News

Pfizer gets approval expansion from FDA for pneumonia vaccine

July 13, 2016
Research and Development, Sales and Marketing FDA, Pfizer, Prevnar 13, adults, approval

The US Food and Drug Administration (FDA) has issued an expanded approval for Pfizer’s pneumococcal pneumonia vaccine Prevnar 13 to …

News
logo

AstraZeneca mulling a $10-billion bid for Medivation – report

July 12, 2016
Manufacturing and Production, Sales and Marketing AstraZeneca, Celgene, Medivation, Pfizer, Xtandi, cancer drug, merger and acquisition

Anglo Swedish drug firm AstraZeneca (LSE: AZN) is considering a $10-billion takeover bid for Medivation (Nasdaq: MDVN), according to reports. …

News
pfizer_building

Pfizer says its Sutent meets primary endpoint in Phase III trials for kidney cancer recurrence

July 11, 2016
Research and Development, Sales and Marketing Kidney cancer, Pfizer, Stutent, drug trial

US pharma giant Pfizer (NYSE: PFE) said late-stage trials for its Sutent (sunitinib) met its primary endpoint as a treatment …

News

Pfizer’s blood cancer drug first to be reappraised from Cancer Drug Fund

July 7, 2016
Research and Development, Sales and Marketing Cancer, Cancer Drugs Fund, NICE, Pfizer, blood cancer, bosulif

The National Institute for Health and Care Excellence (Nice) recommended US pharma giant Pfizer’s (NYSE: PFE) Bosulif (bosutinib) to treat …

News
clinical_trial_3

Merck and Pfizer begin Phase III trials for avelumab in ovarian cancer

July 6, 2016
Research and Development Merck, Pfizer, avelumab

Merck (KGaA, Darmstadt) and Pfizer (NYSE: PFE) have announced the initiation of the first Phase III study of investigational compound, …

News

Pfizer to invest about $350 million in China biotech facility, first in Asia

June 29, 2016
Research and Development, Sales and Marketing Biotech Plant, China, Pfizer, research

US pharma giant Pfizer (NYSE: PFE) said it will invest about $350 million for a global biotechnology center in the …

News

Pfizer breaks ground on new $200 million biologics facility

June 17, 2016
Medical Communications, Research and Development Manufacturing Facility, Pfizer

Pfizer (NYSE: PFE) has broken ground on a new $200 million biologics clinical manufacturing facility in Andover, Massachusetts. This expansion …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026